Bo Angelin

Neurobiology of eating behavior, nutrition, and health

A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia

Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism

An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers

Asynchronous rhythms of circulating conjugated and unconjugated bile acids in the modulation of human metabolism

Treatment with the natural <scp>FXR</scp> agonist chenodeoxycholic acid reduces clearance of plasma <scp>LDL</scp> whilst decreasing circulating <scp>PCSK</scp>9, lipoprotein(a) and apolipoprotein C‐<scp>III</scp>

Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans

Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans

Reductions in serum levels of <scp>LDL</scp> cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome

Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist

Circulating Fibroblast Growth Factors as Metabolic Regulators—A Critical Appraisal

Circulating Human Hepcidin-25 Concentrations Display a Diurnal Rhythm, Increase with Prolonged Fasting, and Are Reduced by Growth Hormone Administration